SUMMARY  

• SPRAVATO nasal spray is intended for administration by the patient under the supervision of a healthcare professional, using 2 devices (for a 56-mg dose) or 3 devices (for an 84-mg dose), with a 5-minute rest between use of each device to allow medication to be absorbed. The nasal spray device is a single-use device that delivers a total of 28 mg of esketamine in two sprays (one spray per nostril). To prevent loss of medication, do not prime the device before use.¹
• The SPRAVATO device has an indicator window which displays 2 green dots when the device is full, one green dot when one spray has been delivered, and no green dots when the device is empty.¹
• Instruct patient to blow nose before first device only.¹
• If during administration, liquid drips out, dab nose with tissue.¹
• Total esketamine absorption after esketamine administration is a combination of local absorption by the nasal mucosa (major route), as well as by the gastrointestinal tract via swallowing.²
• No systematically collected clinical data is available on administering a partial/incomplete dose of SPRAVATO or on management of an incomplete dose of SPRAVATO.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENTDrug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 16 May 2024.